A Study to Determine the Feasibility of Online Recruitment of People Using an Anti-Obesity Medication for Weight Loss

NCT06761703 · Completed

Last updated 2026-05-28

This study tests whether it is possible to recruit people who are using a weight-loss medication online to collect and send their own blood samples for lab testing.

Status Completed The study has finished.

Type Observational

Participants 200 people

Who can join Ages 18–80 · all sexes Healthy volunteers accepted.

Timeline Started 2024-11 · est. completion 2025-01

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT06761703 ↗

Description as written by the study sponsor.

This observational study is designed to determine the feasibility of recruitment from a digital research community of people using an anti-obesity medication for weight loss to understand willingness to consent to survey research and at home self-blood testing. This study will engage an active community of people using anti-obesity medications, semaglutide and tirzepatide, indicated for weight loss to examine the willingness of participants to engage in a digital study, provide consent, and complete various study-related tasks, including a self-collected capillary blood sample for assay testing and health related surveys.

Treatments tested

TAP® Micro Select Device (Touch Activated Phlebotomy) Device

The TAP Micro Select device will be used in an investigational capacity by participants for self-collection of whole capillary blood.

Main thing measured	Number of Participants with Self-blood Draw Received by Central Laboratory
Sponsor	Amgen
Conditions studied	Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06761703 ↗